Keros Therapeutics
Ran Nussbaum has served as Chairman of the board of directors since April 2016. Mr. Nussbaum has served as a Managing Partner and the Co-Founder of The Pontifax Group since January 2004. He also serves as a board member on many of Pontifax’s portfolio companies, including Kite Pharma (acquired by Gilead), ArQule (acquired by Merck & Co.), Ccam Ltd (acquired by Merck & Co.), Prevail Therapeutics (acquired by Eli Lilly), UroGen Pharma and Eloxx Pharmaceuticals.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Keros Therapeutics
2 followers
Keros is dedicated to discovery and development of novel therapeutics for hematological and musculoskeletal disorders.